Oncology is a high cost and high management priority disease state for US payers, however, ability to control cost in this space is limited. MKO Global Partners, a Two Labs Company, conducted previous research that suggests oncology drugs are primarily managed to label and only occasionally are there policies in place to restrict or prefer certain agents. However, new ways to control the cost of oncology care are emerging and are attracting attention. For example, pathways of care are considered a tool of growing relevance. Pathways, with or without risk sharing, are often mentioned as an oncology-specific cost containment tool, alongside other initiatives such as Oncology Care Models, changes in payment mechanisms for providers and, at least in part, value frameworks. Despite the industry interest in pathways of care and other innovative oncology management tools, it is unclear what impact these new approaches will have on access at the local level. To explore this issue in-depth, MKO Global Partners organized a panel discussion with oncologists from different types of provider organizations.
Learn about the three factors that emerged as key issues limiting payers’ ability to manage oncology by downloading this paper.